First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Béla Ózsvári; Federica Sotgia; Michael P. Lisanti

doi:doi:10.18632/aging.103336

← Back

Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 7. Effects of the Mitoriboscin 23/G4 on tumor growth. The Mitoriboscin 23/G4 was tested at higher concentrations of 0.75, 1 and 2 mM. Note that 23/G4, at these concentrations, inhibited tumor growth (by 40% to 60%). Averages are shown + SEM. ***p<0.001.